Central neck lymph node metastasis in oral squamous cell carcinoma at the floor of mouth

Zhang, Songtao; Zhang, Runfang; Wang, Chao; Gong, Wenbo; Xue, Miaomiao; Liu, Lina; Zhang, Yuanyuan

doi:10.1186/s12885-021-07958-7

Cited by 11 publications

(8 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study there was a statistically significant difference in the number of lymph nodes involved across the pathological tumor stage which is comparable to another local study thus confirming the findings. 18 Alsaffar et al in their study on assessment of depth of invasion in tongue OSCC reported the pathological depth of invasion to be greater than the clinical depth. 19 These results were comparable to our study where difference in depth of invasion across the clinical and Primary Tumor stage was clear supporting the clinical decision making based on pathological rather than clinical data.…”

Section: Discussionmentioning

confidence: 97%

Oral Squamous Cell Carcinoma Clinico-pathological features in relation to Tumor Stage; AJCC 2018 perspective

Khan

Naseem²,

Riaz

et al. 2023

Pak J Med Sci

View full text Add to dashboard Cite

Objective: To investigate the association between clinicopathological findings and tumor stage according to AJCC 2018 guidelines in patients suffering from Oral squamous cell carcinoma (OSCC). Methods: A descriptive study was conducted from January 2019 to January 2020 at King Edward Medical University and University of Health Sciences on a total of 49 patients enrolled after obtaining written informed consent. Clinical and radiographic findings were recorded. Pathological reporting was done using AJCC 2018 cancer staging guidelines. Association between clinicopathological features with tumor stage and grade was assessed using Chi-square and Kruskal-Wallis test. Results: Mean age of the patients was 46.1 ± 10.6 years. Most of the tumors were of well differentiated type (49%) and moderately differentiated (40.8%) with predominant clinical stage III in 42.9% & IV in 44.9 % and primary tumor stage pT2 28.6% & pT3 36.7%. Significant difference was seen for primary tumor stage in relation to age, gender, depth of invasion, primary site, and size of tumor (p < 0.01). For clinical stages, significant difference was observed in the age, gender, size of tumor, nodal metastasis, and anatomical tumor site (p < 0.01). Conclusion: Application of 8th Edition AJCC guidelines identifies the importance of the latest classification with strong association of latest stage criteria with age, gender, site of primary tumor, tumor thickness, depth of invasion, nodal metastasis and size of largest lymph node involved, and Level of Lymph node involved (level III & V) in a subset of patients from a developing country. doi: https://doi.org/10.12669/pjms.39.2.7266 How to cite this: Khan NR, Naseem N, Riaz N, Anjum R, Khalid S, Iqbal A, et al. Oral Squamous Cell Carcinoma Clinico-pathological features in relation to Tumor Stage; AJCC 2018 perspective. Pak J Med Sci. 2023;39(2):---------. doi: https://doi.org/10.12669/pjms.39.2.7266 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Discussionmentioning

confidence: 97%

Oral Squamous Cell Carcinoma Clinico-pathological features in relation to Tumor Stage; AJCC 2018 perspective

Khan

Naseem²,

Riaz

et al. 2023

Pak J Med Sci

View full text Add to dashboard Cite

show abstract

“…Recurrence and metastasis are generally considered to be the major causes of OSCC-related deaths [ 7 ]. Cervical lymphatic metastasis is the most common form of metastasis, which is associated with poor prognosis [ 34 , 35 ]. Nowadays, surgery is still the main treatment for OSCC [ 36 ] and neck lymphadenectomy is an effective way to treat or prevent neck metastasis of OSCC [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

ENO1 Binds to ApoC3 and Impairs the Proliferation of T Cells via IL-8/STAT3 Pathway in OSCC

Wang

Man

Zhong

et al. 2022

IJMS

View full text Add to dashboard Cite

Lymph node metastasis is associated with poor prognosis of oral squamous cell carcinoma (OSCC), and few studies have explored the relevance of postoperative lymphatic drainage (PLD) in metastatic OSCC. Alpha-enolase (ENO1) is a metabolic enzyme, which is related to lymphatic metastasis of OSCC. However, the role of ENO1 in PLD in metastatic OSCC has not been elucidated. Herein, we collected lymphatic drainage after lymphadenectomy between metastatic and non-metastatic lymph nodes in OSCC patients to investigate the relationship between ENO1 expression and metastasis, and to identify the proteins which interacted with ENO1 in PLD of patients with metastatic OSCC by MS/GST pulldown assay. Results revealed that the metabolic protein apolipoprotein C-III (ApoC3) was a novel partner of ENO1. The ENO1 bound to ApoC3 in OSCC cells and elicited the production of interleukin (IL)-8, as demonstrated through a cytokine antibody assay. We also studied the function of IL-8 on Jurkat T cells co-cultured with OSCC cells in vitro. Western blot analysis was applied to quantitate STAT3 (signal transducer and activator of transcription 3) and p-STAT3 levels. Mechanistically, OSCC cells activated the STAT3 signaling pathway on Jurkat T cells through IL-8 secretion, promoted apoptosis, and inhibited the proliferation of Jurkat T cells. Collectively, these findings illuminate the molecular mechanisms underlying the function of ENO1 in metastasis OSCC and provide new strategies for targeting ENO1 for OSCC treatment.

show abstract

“…All pathologic sections were re-reviewed by at least two head and neck pathologists. Abnormal lymph node enlargement on CT was defined as follows: an area with clear evidence of nonfat, low-density, or liquid components; largest diameter of node > 15 mm at level II and > 10 mm at other levels; and a ratio of the longest to smallest diameter ≤ 2 mm 8 .…”

Section: Methodsmentioning

confidence: 99%

Clinical parameters predictors of malignant transformation of recurrent parotid pleomorphic adenoma

2023

Sci Rep

View full text Add to dashboard Cite

Malignant transformation (MT) in recurrent parotid pleomorphic adenomas (PAs) is rare; therefore its occurrence lacks reliable predictive factors. Our goal was to clarify the predictors for MT of recurrent parotid PAs based on preoperative clinical parameters. Patients with a clinical diagnosis of recurrent parotid PA were retrospectively enrolled. The association between clinicopathologic variables and MT of PA was assessed using univariate and multivariate analyses. MT occurred in 11.8% of the 467 patients. In univariate analysis, three or more previous recurrences, newly developed facial nerve paralysis, difficulty in mouth opening, tumors with the largest tumor diameter ≥ 2.4 cm, and abnormal neck lymph node enlargement were associated with MT occurrence. Further, multivariate analysis showed that three or more previous recurrences, newly developed facial nerve paralysis, difficulty in mouth opening, and abnormal neck lymph node enlargement were independently related to MT. MT of recurrent PA was not uncommon. Clinical signs of malignancy included newly developed facial nerve paralysis, difficulty in mouth opening, three or more previous recurrences, and abnormal neck lymph node enlargement.

show abstract

Central neck lymph node metastasis in oral squamous cell carcinoma at the floor of mouth

Cited by 11 publications

References 27 publications

Oral Squamous Cell Carcinoma Clinico-pathological features in relation to Tumor Stage; AJCC 2018 perspective

Oral Squamous Cell Carcinoma Clinico-pathological features in relation to Tumor Stage; AJCC 2018 perspective

ENO1 Binds to ApoC3 and Impairs the Proliferation of T Cells via IL-8/STAT3 Pathway in OSCC

Clinical parameters predictors of malignant transformation of recurrent parotid pleomorphic adenoma

Contact Info

Product

Resources

About